A primary breast cancer with distinct foci of estrogen receptor-alpha positive and negative cells derived from the same clonal origin as revealed by whole exome sequencing
Tumor heterogeneity is a now well-recognized phenomenon that can affect the classification, prognosis and treatment of human cancers. Heterogeneity is often described in primary breast cancers based upon histologic subtypes, hormone- and HER2-receptor status, and immunolabeling for various markers, which can be seen within a single tumor as mixed cellular populations, or as separate discrete foci.
Here, we present a case report of a patient’s primary breast cancer that had two separate but adjacent histologic components, one that was estrogen receptor (ER) positive, and the other ER negative. Each component was subjected to whole exome sequencing and compared for gene identity to determine clonal origin.
Using prior bioinformatic tools, we demonstrated that both the ER positive and negative components shared many variants, including passenger and driver alterations. Copy number variations also supported the two components were derived from a single common clone.
These analyses strongly suggest that the two ER components of this patient’s breast cancer were derived from the same clonal origin. Our results have implications for the evolution of breast cancers with mixed histologies, and how they might be best managed for optimal therapy.
KeywordsWhole exome sequencing Breast cancer Estrogen receptor
We thank various members of the Park and Wheelan lab for helpful thoughts and discussions. This work was supported by NIH R01CA194024, NIH P30CA006973, Susan G. Komen, the Commonwealth Foundation, the Breast Cancer Research Foundation, the Marcie Ellen Foundation, The Helen Golde Trust, and The Canney Foundation. None of the funding sources influenced the design, interpretation or submission of this manuscript.
B.H.P. is a paid member of scientific advisory boards for Loxo Oncology, and has ownership interest in Loxo Oncology. B.H.P. has research contracts with Foundation Medicine, Inc. Under separate licensing agreements between Horizon Discovery, LTD and The Johns Hopkins University, B.H.P. is entitled to a share of royalties received by the University on sales of products. The terms of this arrangement are being managed by the Johns Hopkins University, in accordance with its conflict of interest policies. No potential conflicts of interest were disclosed by the other authors.
- 1.Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S et al (2010) American Society of clinical oncology/College Of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784–2795CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Avigdor BE, Beierl K, Gocke CD, Zabransky DJ, Cravero K, Kyker-Snowman K et al (2017) Whole-exome sequencing of metaplastic breast carcinoma indicates monoclonality with associated ductal carcinoma component. Clin Cancer Res 23(16):4875–4884. https://doi.org/10.1158/1078-0432.CCR-17-0108 CrossRefPubMedGoogle Scholar
- 9.Cingolani P, Platts A, le Wang L, Coon M, Nguyen T, Wang L et al (2012) A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: sNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6(2):80–92. https://doi.org/10.4161/fly.19695 CrossRefGoogle Scholar
- 14.Sharma D, Blum J, Yang X, Beaulieu N, Macleod AR, Davidson NE (2005) Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol Endocrinol 19(7):1740–1751. https://doi.org/10.1210/me.2004-0011 CrossRefPubMedGoogle Scholar